Drug Profile


Alternative Names: EC-145; Folic acid desacetylvinblastine hydrazine conjugate; MK-8109; VYNFINIT

Latest Information Update: 04 Sep 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Class Amino acids; Antineoplastics; Folic-acids; Hydrazines; Pterins; Sulfhydryl compounds; Vinca alkaloids
  • Mechanism of Action Microtubule protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Ovarian cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Preregistration Submission Withdrawal Ovarian cancer
  • No development reported Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 07 Sep 2015 Final efficacy and adverse events data from a phase II trial in Non Small Cell Lung Cancer released by Endocyte
  • 01 Sep 2015 Discontinued - Phase-II for Endometrial cancer (Late-stage disease) in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top